Liraglutide pharmacotherapy reduces body weight and improves glycemic control in juvenile obese / hyperglycemic male and female rats

ConclusionThese preclinical data suggest that maternal and early ‐life consumption of HFSD increases caloric intake, body weight gain and hyperglycemia, a collective set of unwanted metabolic effects that appear to be treatable in juveniles with liraglutide pharmacotherapy intervention.This article is protected by copyright. All rights reserved.
Source: Diabetes, Obesity and Metabolism - Category: Endocrinology Authors: Tags: ORIGINAL ARTICLE Source Type: research